Article

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

2025-06-24

Abstract excerpt

<h4>SUMMARY</h4> Colorectal cancer (CRC) remains the second-leading cause of cancer-associated deaths, indicating an urgent need for improved therapeutic options. We previously generated antibody-drug conjugates (ADCs) targeting the cancer stem-like cell marker leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). However, tumor relapse due to LGR5 downregulation and suboptimal payload selection war...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 06013573-b8cb-5b8e-bbb3-5e1cd4e55ae1
DOI: 10.1101/2025.06.18.660406

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer modelsDOI 10.1101/2025.06.18.660406Read

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerSemantic proximity Read

LGR5 targeting molecules as therapeutic agents for multiple cancer typesSemantic proximity Read

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Semantic proximity Read

Novel immunotherapeutics against LGR5 to target multiple cancer typesSemantic proximity Read

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Semantic proximity Read

LGR5‐Positive Colon Cancer Stem Cells Interconvert with Drug‐Resistant LGR5‐Negative cells and are Capable of Tumor ReconstitutionSemantic proximity Read

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read

[Anti-EGFR antibody therapy for colorectal cancer].Semantic proximity Read

Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC.Semantic proximity Read

Monoclonal Antibodies Against Lgr5 Identify Human Colorectal Cancer Stem CellsSemantic proximity Read

Development of gemcitabine-modified miR-15a as a novel, multimodal treatment strategy to overcome 5-FU and oxaliplatin resistance in colorectal cancerSemantic proximity Read